Antihypertensive therapy: how to evaluate the benefits

Area of Science:

• Cardiovascular Medicine
• Health Economics
• Public Health Policy

Background:

• Antihypertensive therapy benefits are traditionally assessed via randomized trials focusing on cardiovascular events.
• Broader benefits include preventing congestive heart failure, left ventricular hypertrophy, and hypertension progression.
• Quantifying these benefits for cost-effectiveness analysis presents challenges.

Purpose of the Study:

• To evaluate the cost-effectiveness of antihypertensive therapy.
• To compare the traditional randomized trial approach with an actuarial approach for assessing treatment benefits.
• To inform healthcare decision-makers on optimizing antihypertensive treatment strategies.

Main Methods:

• Review of randomized trials monitoring cardiovascular events.
• Application of an actuarial approach using life expectancy data associated with blood pressure reduction.
• Comparative analysis of cost-effectiveness between the two methodologies.

Main Results:

• Randomized trials may underestimate long-term treatment benefits due to limited duration.
• The actuarial approach demonstrates a significantly lower cost per year of life gained from antihypertensive therapy.
• Limiting treatment decisions solely on absolute risk may exclude eligible patients.

Conclusions:

• Both randomized trial and actuarial approaches are crucial for comprehensive cost-effectiveness evaluation of antihypertensive therapy.
• Physicians, patients, and policymakers should consider both methodologies for informed treatment decisions.
• A broader perspective on benefits enhances the value of antihypertensive interventions.